The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
Allison E B ChangAndrew J Piper-VallilloRaymond H MakMichael LanutiAlona MuzikanskyJulia RotowPasi A JänneMari Mino-KenudsonScott SwansonCameron D WrightDavid KozonoPaul MarcouxZofia PiotrowskaLecia V SequistHenning WillersPublished in: The oncologist (2024)
We explored the efficacy of combining TKI with cCRT in oncogene-driven NSCLC. Induction TKI did not compromise subsequent receipt of multimodality therapy. PFS was promising, but the prevalence of CNS-only recurrences and rapid progression after TKI discontinuation speak to unmet needs in measuring and eradicating micrometastatic disease.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- small cell lung cancer
- minimally invasive
- risk factors
- coronary artery bypass
- open label
- study protocol
- clinical trial
- rectal cancer
- phase iii
- chronic myeloid leukemia
- blood brain barrier
- locally advanced
- stem cells
- randomized controlled trial
- squamous cell carcinoma
- wild type
- double blind
- cell therapy
- acute coronary syndrome
- brain metastases
- bone marrow
- surgical site infection
- percutaneous coronary intervention